$CNCE News Article - Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE?AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
https://marketwirenews.com/news-releases/conc...34109.html